Explore the words cloud of the anTBiotic project. It provides you a very rough idea of what is the project "anTBiotic" about.
The following table provides information about the project.
GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL
|Coordinator Country||Spain [ES]|
|Total cost||5˙819˙416 €|
|EC max contribution||5˙819˙416 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2017-01-01 to 2021-12-31|
Take a look of project's partnership.
|1||GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL||ES (TRES CANTOS)||coordinator||1˙923˙768.00|
|2||TASK FOUNDATION NPC||ZA (CAPE TOWN)||participant||1˙873˙804.00|
|3||FORSCHUNGSZENTRUM BORSTEL||DE (BORSTEL)||participant||1˙242˙417.00|
|4||UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET||NO (TROMSO)||participant||644˙072.00|
|5||UNIVERSITY OF CAPE TOWN||ZA (RONDEBOSCH)||participant||135˙353.00|
Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been higher and the growing proportion of drug-resistant TB is threatening control strategies both in the developing and developed world, Eastern Europe being a particularly worrying point in case. The anTBiotic consortium aims to fuel the long-term TB clinical pipeline while immediately offering new options to clinicians when confronted with multidrug-resistant (MDR)-TB. More specifically, the proposed studies aim to:
a) Establish the proof of concept of anti-TB efficacy in humans of a pioneering, first-in-class, low-dose GSK oxaborole clinical drug candidate; b) Identify a combination of β-lactam antibiotics suitable for the treatment of MDR TB orally or as a once daily intravenous or intramuscular application and c) Incorporate the best β-lactam combination into an explorative salvage regimen for untreatable patients with extensively drug-resistant TB
The anti-TB activity in humans will be established in a two-week EBA clinical studies that combine established (CFU, TTP) and new clinical markers (biomarkers, PET/CT). These datasets will help ascertain anti-TB efficacy in humans and generate confidence on their validity in longer-term drug combination trials. A variety of modelling approaches to predict optimal dosing will be used. Finally, we intend to use at least one of these novel anti-TB entities as part of a pioneering, non-controlled clinical trial in highly drug resistant subjects in Europe and South Africa. This final clinical intervention will hopefully be of immediate benefit to drug-resistant patients in the EU and elsewhere in addition to generating a strong precedent for further adoption worldwide.
|Project Website||Websites, patent fillings, videos etc.||2019-06-14 12:42:31|
|Dissemination Plan||Documents, reports||2019-06-14 12:42:31|
Take a look to the deliverables list in detail: detailed list of anTBiotic deliverables.
|year||authors and title||journal||last update|
Fabrizio Clarelli, Jingyi Liang, Antal Martinecz, Ines Heiland, Pia Abel zur Wiesch
Multi-scale modeling of drug binding kinetics to predict drug efficacy
published pages: , ISSN: 1420-682X, DOI: 10.1007/s00018-019-03376-y
|Cellular and Molecular Life Sciences||2020-02-13|
Veronique R. de Jager, Naadira Vanker, Lize van der Merwe, Elana van Brakel, Morris Muliaditan, Andreas H Diacon
Optimising Î²-lactams Against Tuberculosis
published pages: , ISSN: 1073-449X, DOI: 10.1164/rccm.201911-2149le
|American Journal of Respiratory and Critical Care Medicine||2020-02-13|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANTBIOTIC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ANTBIOTIC" are provided by the European Opendata Portal: CORDIS opendata.
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Integrating and decentralising diabetes and hypertension services in AfricaRead More